Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Medpace Holdings, Inc.
MEDP
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $15.5B
$560.29
▲ +3.08%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$306.70 - $628.92
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 66.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Integrated full-service platform reducing client complexity and improving efficiency
- Established relationships with pharmaceutical and biotech sponsors built over 30+ years
- Specialized expertise across multiple therapeutic areas and trial phases
- Global infrastructure enabling multi-region trial execution and regulatory navigation
Bear Case
2 risks
- Average volatility.
- Premium valuation to Life Sciences Tools peers
Growth
Stable outlook
Increasing pharmaceutical R&D spending and clinical trial outsourcing adoption
Value
Premium valuation to Life Sciences Tools peers
Momentum
Strong
+9.1% over 3m
Quality
Stable
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying MEDP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 20, 2026
APR 22, 2026
Reported EPS of $4.28 vs $3.92 consensus (+9.2% surprise). Revenue of $706.6M vs $697.6M expected (+1.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+9.2%
Next: Apr 20, 2026
Revenue trend · last 8Q
—
—
+8%
+9%
+14%
+24%
+32%
+27%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$528.1M
$533.3M
$536.6M
$558.6M
$603.3M
$659.9M
$708.5M
$706.6M
Margins · last 8Q
Gross
27.8%
Operating
20.0%
Profit
17.5%
Wall Street consensus
8 analysts · 38% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
38%
Hold
63%
Sell
0%
Median Price Target
$463.50
▼ -17.3% vs $560.29
Latest: Baird · $477.00 · Apr 24, 2026
4 analysts covering